USTR Takes Aim At Colombia Over Drug Pricing Policy
Executive Summary
Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.
You may also be interested in...
Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies
Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.